Cargando…
Pharmacogenomics of chronic hepatitis C therapy with genome-wide association studies
Chronic hepatitis C (CHC) is a liver disease characterized by infection with the hepatitis C virus (HCV) persisting for more than six months. Patients with CHC often stop pursuing the pegylated interferon (peg-IFN) and ribavirin (RBV) treatment because of the high cost and associated adverse effects...
Autores principales: | Wang, Chun-Hsiang, Hwang, Yuchi, Lin, Eugene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863289/ https://www.ncbi.nlm.nih.gov/pubmed/27186094 |
Ejemplares similares
-
Pharmacogenomics of drug efficacy in the interferon treatment of chronic hepatitis C using classification algorithms
por: Ke, Wan-Sheng, et al.
Publicado: (2010) -
Pharmacogenomics of hepatitis C infections: personalizing therapy
por: Booth, David R, et al.
Publicado: (2012) -
Genome-wide association studies on HIV susceptibility, pathogenesis and pharmacogenomics
por: van Manen, Daniëlle, et al.
Publicado: (2012) -
Clinical utility of pharmacogenomics in the management of hepatitis C
por: Trinks, Julieta, et al.
Publicado: (2014) -
Detecting Signals in Pharmacogenomic Genome-Wide Association Studies
por: Wakefield, Jon, et al.
Publicado: (2014)